• Home
  • News
    • Editorial
    • MD(e)B(unker)
    • Related Researches
      • Di Bella's Foundation
      • 1960-1969
      • 1970-1979
      • 1980-1989
      • 1990-1999
      • 2000-2009
      • 2010-2019
      • 2020-2029
    • Science news
    • Scientific Documentation
  • About us...
    • Biography
    • Bibliography
  • The Method
    • Di Bella's Method!
    • 1998 Trial!
  • Media
    • Video Publications
    • News-PapersNews-Papers
      • Press
    • TestimonialTestimonial
      • Testimonies
    • Video GalleryVideo Gallery
      • Congresses
      • Video Testimonies
      • TV & C.
  • Case History
    • Medical reports
      • Lung
      • Lymphomas
        • Non-Hodgkin Lymphomas
        • Hodgkin Lymphomas
      • Mediastinum
      • Mesothelioma
      • Myeloma
      • Pancreas
      • Scientific Publications
  • F.A.Q.
  • Useful Links
    • User Side
      • Vademecum
    • CouponChief - Resources for Cancer Patients
  • Contact Us
Home page   News   Related Researches   1990-1999  
Title Created Date
Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography 19 August 2013
The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines 14 August 2013
The validity of melatonin as an oncostatic agent 13 August 2013
Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160 22 July 2013
Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients 22 July 2013
Growth inhibition and apoptosis of RL human B lymphoma cells by vitamin E succinate and retinoic acid: role for transforming growth factor beta 16 July 2013
Somatostatin receptors and breast cancer 15 July 2013
Retinoic acid-induced apoptosis and regression of a refractory Epstein-Barr virus-containing T cell lymphoma expressing multidrug-resistance phenotypes 15 July 2013
13-cis-retinoic acid induces cellular differentiation and durable remission in refractory cutaneous Ki-1 lymphoma 07 July 2013
Growth-hormone and prolactin excess 06 July 2013
Display # 

Page 57 of 60

  • Start
  • Prev
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • Next
  • End

Search

Follow us...

Latest

  • Beneficial properties of melatonin in an experimental model of pancreatic cancer
  • Combinatory Effects of Indoximod and Melatonin Alleviate Myeloid Derived Suppressor Cells Driven Triple Negative Breast Cancer Progression and Metastasis
  • Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling
  • Vitamin D decreases tumor cell growth and invasiveness in primary malignant bone tumors in vitro
  • Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial
  • Synergistic In Vitro Effects of Minor Phytocannabinoids and Melatonin Combinations Against Human Glioblastoma Cells
  • Melatonin as a Promising Agent to Treat Ovarian Cancer: Molecular Mechanisms
  • Pharmacologic targeting of the dopamine D2 receptor impacts the efficacy of immune checkpoint blockade in melanoma
  • Dose-Dependency of Antitumor Effects of the Pineal Hormone Melatonin in Untreatable Metastatic Solid Tumor Patients
  • Impaired redox adaptation through SLC38A5-dependent glutamine metabolism contributes to melatonin-mediated anoikis sensitivity and metastasis suppression in bone cancer
  • Does the use of melatonin overcome drug resistance in cancer chemotherapy?
  • Adjuvant chemotherapy with melatonin for targeting human cancers: A review
  • A Preliminary Phase-2 Study with very High-Dose of Melatonin (1000 mg/day) in Untreatable Advanced Cancer Patients Already Progression on Previous Palliative Therapy with High-Dose Melatonin
  • Melatonin and Vitamins: A Promising Combination to Augment Conventional Anticancer Therapies
  • Neuroimmune treatment of advanced solid tumors: 3-year survival after angiotensin 1-7, pineal indoles, and cannabinoids
  • Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
  • Melatonin: A Powerful Integrative Adjunctive Agent for Oncology
  • Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives

Most Read

  • The Di Bella Method (DBM)
  • About melatonin - 1996
  • All-trans-retinoic acid and cancer
  • Biography
  • Chronic Lymphocytic Leukemia: 4 patients, long-lasting remission
  • The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer
  • Somatostatin in oncology, the overlooked evidences
  • Treatment of Low-grade Non-Hodgkin’s Lymphomas at Advanced Stage
  • How effective is chemo therapy?
  • Complete objective response to biological therapy of plurifocal breast carcinoma
  • Bibliography
  • Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report
  • Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report
  • Vademecum
  • Frequently Asked Questions
  • Declaration recommends eliminate the use of Impact factor for research evaluation
  • Non–Small-Cell Lung Cancer Patients with Low Performance Status: study on 28 patients
  • Breast cancer: study on 122 cases. The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer